Recommend Human Vaccines to your librarian for 2008. Download form here.
Email this page
Print this page
Short Report
Preclinical Evaluation of a Chimeric Malaria Vaccine Candidate in Montanide ISA 720®: Immunogenecity and Safety in Rhesus Macaques
Jan A.M. Langermans, Meike Hensman, Marcel van Gijlswijk, Dongmei Zhang, Weiqing Pan, Birgitte K. Giersing, Emily Locke, F. Dubovsky, Janet Wittes, A.W. Thomas
volume 2 | issue 5
september/october 2006Pages: 222 - 226
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDF If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.
Several malarial antigens are in development as potential vaccine candidates as part of a concerted effort to control the disease, which kills more than one million people per year. Although some antigens have demonstrated an impact against the malaria parasite, Plasmodium falciparum, many researchers hypothesize that a combination of antigens will be required to generate high levels of efficacy against clinical disease. PfCP2.9 is a chimeric protein that includes MSP119 and domain III of AMA1 [AMA1 (III)] of Plasmodium falciparum in a single recombinant molecule. The antigen, formulated in Seppic’s ISA 720 adjuvant, is approaching Phase I clinical testing in humans.
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDF If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.